Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

Guillem Argiles,Rodrigo Dienstmann,Marta Benavent Viñuales,Andrés Cervantes,Susana Rosello Keranen,Ulla H. Hansen,Niels Jorgen Ostergaard Skartved,Ivan D. Horak,Stephan Braun,Rocío García Carbonero

Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.

2014

Guillem Argiles
Rodrigo Dienstmann
Marta Benavent Viñuales
Andrés Cervantes
Susana Rosello Keranen
Ulla H. Hansen
Niels Jorgen Ostergaard Skartved
Ivan D. Horak
Stephan Braun
Rocío García Carbonero

3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti-EGFR mAb treatment (eg, cetuximab or panitumumab). Sym004 is the first-...

Keywords:

Anti-EGFR Monoclonal Antibody
Pathology
Colorectal cancer
Monoclonal antibody
Cancer research
Medicine
KRAS
Panitumumab
Cetuximab
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations